Advanced

Treatment for patients with relapsed/refractory mantle cell lymphoma : European-based recommendations

Dreyling, Martin; Aurer, Igor; Cortelazzo, Sergio; Hermine, Olivier; Hess, Georg; Jerkeman, Mats LU ; Le Gouill, Steven; Ribrag, Vincent; Trněný, Marek and Visco, Carlo, et al. (2017) In Leukemia and Lymphoma
Abstract

Patients with mantle cell lymphoma (MCL) usually respond to initial combination chemotherapy, but the disease inevitably relapses and often follows an aggressive course. Here, clinical study results published since 2008 for patients with relapsed/refractory MCL were reviewed to compare available evidence for treatment guidance. Most trials identified were non-randomized, phase II studies performed at a limited number of sites, and many evaluated MCL as one of multiple non-Hodgkin lymphoma subtypes. Additional randomized, comparative trials are needed. Treatment selection generally depends on patient need, age and fitness, time of relapse, and line of therapy. Combination regimens typically produce higher response rates than single... (More)

Patients with mantle cell lymphoma (MCL) usually respond to initial combination chemotherapy, but the disease inevitably relapses and often follows an aggressive course. Here, clinical study results published since 2008 for patients with relapsed/refractory MCL were reviewed to compare available evidence for treatment guidance. Most trials identified were non-randomized, phase II studies performed at a limited number of sites, and many evaluated MCL as one of multiple non-Hodgkin lymphoma subtypes. Additional randomized, comparative trials are needed. Treatment selection generally depends on patient need, age and fitness, time of relapse, and line of therapy. Combination regimens typically produce higher response rates than single agents, and adding rituximab generally improves outcomes. The inclusion of ibrutinib, lenalidomide, temsirolimus, and bortezomib, represents an important advance for patients ineligible for, unable to tolerate, or failing high-intensity combination chemotherapy. A high need for effective treatments in relapsed/refractory MCL remains, particularly for elderly and frail patients.

(Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
epub
subject
keywords
Chemotherapy, clinical trials, mantle cell lymphoma, molecular targeted therapy
in
Leukemia and Lymphoma
pages
15 pages
publisher
Taylor & Francis
external identifiers
  • scopus:85035101611
ISSN
1042-8194
DOI
10.1080/10428194.2017.1403602
language
English
LU publication?
yes
id
918ffd12-a1d8-45f8-a58d-78eaf4aeb784
date added to LUP
2017-12-14 14:20:05
date last changed
2018-04-29 04:44:23
@article{918ffd12-a1d8-45f8-a58d-78eaf4aeb784,
  abstract     = {<p>Patients with mantle cell lymphoma (MCL) usually respond to initial combination chemotherapy, but the disease inevitably relapses and often follows an aggressive course. Here, clinical study results published since 2008 for patients with relapsed/refractory MCL were reviewed to compare available evidence for treatment guidance. Most trials identified were non-randomized, phase II studies performed at a limited number of sites, and many evaluated MCL as one of multiple non-Hodgkin lymphoma subtypes. Additional randomized, comparative trials are needed. Treatment selection generally depends on patient need, age and fitness, time of relapse, and line of therapy. Combination regimens typically produce higher response rates than single agents, and adding rituximab generally improves outcomes. The inclusion of ibrutinib, lenalidomide, temsirolimus, and bortezomib, represents an important advance for patients ineligible for, unable to tolerate, or failing high-intensity combination chemotherapy. A high need for effective treatments in relapsed/refractory MCL remains, particularly for elderly and frail patients.</p>},
  author       = {Dreyling, Martin and Aurer, Igor and Cortelazzo, Sergio and Hermine, Olivier and Hess, Georg and Jerkeman, Mats and Le Gouill, Steven and Ribrag, Vincent and Trněný, Marek and Visco, Carlo and Walewski, Jan and Zaja, Francesco and Zinzani, Pier Luigi},
  issn         = {1042-8194},
  keyword      = {Chemotherapy,clinical trials,mantle cell lymphoma,molecular targeted therapy},
  language     = {eng},
  month        = {11},
  pages        = {15},
  publisher    = {Taylor & Francis},
  series       = {Leukemia and Lymphoma},
  title        = {Treatment for patients with relapsed/refractory mantle cell lymphoma : European-based recommendations},
  url          = {http://dx.doi.org/10.1080/10428194.2017.1403602},
  year         = {2017},
}